Wulff, Hansen & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$669K Buy
558
+3
+0.5% +$3.06K 0.51% 53
2026
Q1
$510K Hold
555
– – 0.52% 57
2025
Q4
$596K Hold
555
– – 0.5% 54
2025
Q3
$423K Sell
555
-230
-29% -$171K 0.36% 68
2025
Q2
$612K Hold
785
– – 0.52% 54
2025
Q1
$648K Hold
785
– – 0.59% 51
2024
Q4
$606K Hold
785
– – 0.57% 48
2024
Q3
$695K Sell
785
-250
-24% -$225K 0.63% 48
2024
Q2
$937K Hold
1,035
– – 0.93% 40
2024
Q1
$805K Hold
1,035
– – 0.8% 41
2023
Q4
$603K Hold
1,035
– – 0.67% 45
2023
Q3
$556K Sell
1,035
-850
-45% -$438K 0.65% 46
2023
Q2
$884K Hold
1,885
– – 0.99% 33
2023
Q1
$647K Buy
+1,885
New +$636K 0.74% 46

Other funds holding LLY

Wulff, Hansen & Co's LLY Position: Q2 2026 in Review

Wulff, Hansen & Co increased its Eli Lilly (LLY) stake by 0.54% in Q2 2026, buying an estimated $3.06K and bringing the position to 558 shares worth $669K. The position accounts for 0.51% of the portfolio, ranked #53.

Wulff, Hansen & Co first reported a position in LLY in Q1 2023 and has held it in 14 quarters since. The position peaked at $937K in Q2 2024. 4,642 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Wulff, Hansen & Co held 558 shares of Eli Lilly worth $669K as of Q2 2026.
  • Wulff, Hansen & Co bought 3 Eli Lilly shares in Q2 2026, an estimated $3.06K.
  • Eli Lilly made up 0.51% of Wulff, Hansen & Co's portfolio in Q2 2026, its #53 holding.
  • Wulff, Hansen & Co first reported a position in Eli Lilly in Q1 2023 and has held it in 14 quarters since.
  • Wulff, Hansen & Co's Eli Lilly position peaked at $937K in Q2 2024.
  • 4,642 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Wulff, Hansen & Co's 13F filing for Q2 2026, filed 5 Aug 2026.